THOR: a TMB heterogeneity-adaptive optimization model predicts immunotherapy response using clonal genomic features in group-structured data.

Authors: Wang, Yixuan¹ (AUTHOR), Guan, Yanfang^2,3 (AUTHOR), Lai, Xin² (AUTHOR), Liu, Yuqian² (AUTHOR), Chang, Zhili^2,4 (AUTHOR), Wang, Xiaonan^2,4 (AUTHOR), Wang, Quan¹ (AUTHOR), Liu, Jingjing¹ (AUTHOR), Zhao, Jian¹ (AUTHOR), Yang, Shuanying⁵ (AUTHOR), Wang, Jiayin² (AUTHOR), Song, Xiaofeng¹ (AUTHOR)

Source: Briefings in Bioinformatics. Jan2025, Vol. 26 Issue 1, p1-15. 15p.

Subject Terms: *Parameter estimation, Immune checkpoint inhibitors, Inferential statistics, Multisensor data fusion, Clinical medicine

Gut microbial predictors of first-line immunotherapy efficacy in advanced NSCLC patients.

Authors: Grenda, Anna¹ (AUTHOR) annna.grenda@umlub.pl, Iwan, Ewelina² (AUTHOR), Kuźnar-Kamińska, Barbara³ (AUTHOR), Bomba, Arkadiusz² (AUTHOR), Bielińska, Katarzyna² (AUTHOR), Krawczyk, Paweł¹ (AUTHOR), Chmielewska, Izabela¹ (AUTHOR), Frąk, Małgorzata¹ (AUTHOR), Szczyrek, Michał¹ (AUTHOR), Rolska-Kopińska, Anna¹ (AUTHOR), Jankowski, Tomasz¹ (AUTHOR), Kieszko, Robert¹ (AUTHOR), Milanowski, Janusz¹ (AUTHOR)

Source: Scientific Reports. 3/10/2025, Vol. 15 Issue 1, p1-12. 12p.

Subject Terms: *TREATMENT effectiveness, *IMMUNE checkpoint inhibitors, *NON-small-cell lung carcinoma, *HYPERVARIABLE regions, *OVERALL survival, *GUT microbiome

Comparison analysis of ICIs and chemotherapy combined with or without lenvatinib as first-line treatment of unresectable intrahepatic cholangiocarcinoma.

Authors: Li, Miao¹ (AUTHOR), Li, Tong¹ (AUTHOR), Chen, Rongxin¹ (AUTHOR), Wang, Yan¹ (AUTHOR) wang.yan2@zs-hospital.sh.cn

Source: BMC Cancer. 3/12/2025, Vol. 25 Issue 1, p1-11. 11p.

Subject Terms: *PROPORTIONAL hazards models, *IMMUNE checkpoint inhibitors, *MEDICAL sciences, *GROUP psychotherapy, *OVERALL survival

Co-delivery of axitinib and PD-L1 siRNA for the synergism of vascular normalization and immune checkpoint inhibition to boost anticancer immunity.

Authors: Liu, Yanhong^1,2 (AUTHOR), Gong, Liming^1,3 (AUTHOR), Feng, Jing^1,3 (AUTHOR), Xiao, Congcong^1,3 (AUTHOR), Liu, Chenfei^1,3 (AUTHOR), Chen, Bohan^1,3 (AUTHOR), Chen, Liqing^1,3 (AUTHOR), Jin, Mingji^1,3 (AUTHOR), Guan, Youyan⁴ (AUTHOR) guanyouyan@cicams.ac.cn, Gao, Zhonggao^1,3 (AUTHOR) zggao@imm.ac.cn, Huang, Wei^1,3 (AUTHOR) huangwei@imm.ac.cn

Source: Journal of Nanobiotechnology. 3/10/2025, Vol. 23 Issue 1, p1-22. 22p.

Subject Terms: *IMMUNE checkpoint inhibitors, *CYTOTOXIC T cells, *MEDICAL sciences, *VASCULAR endothelial cells, *KILLER cells, *NEOVASCULARIZATION

Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer.

Authors: Wang, Yanrong^1,2,3 (AUTHOR), Jia, Ru³ (AUTHOR), Si, Haiyan³ (AUTHOR), Ma, Yue^1,2 (AUTHOR), Fan, Mengjiao^1,2 (AUTHOR), Zhang, Nan^1,2 (AUTHOR), Liu, Fangfang³ (AUTHOR), Shi, Yue³ (AUTHOR), Jia, Yushan³ (AUTHOR), Zhang, Yaoyue³ (AUTHOR), Han, Quanli² (AUTHOR) hanquanli@aliyun.com, Wang, Zhikuan³ (AUTHOR) wangzkme@sohu.com, Dai, Guanghai³ (AUTHOR) daigh301@vip.sina.com

Source: BMC Cancer. 3/7/2025, Vol. 25 Issue 1, p1-11. 11p.

Subject Terms: *COLORECTAL liver metastasis, *IMMUNE checkpoint inhibitors, *METASTASIS, *COLORECTAL cancer, *PATIENT safety

Efficacy and safety of PD-1/PD-L1 inhibitors for natural killer/T-cell lymphoma: a single-arm meta-analysis.

Authors: Yang, Jiao¹ (AUTHOR), Xue, Xinyu¹ (AUTHOR), Ma, Yanfeng¹ (AUTHOR), Wang, Xuemei^1,2 (AUTHOR), Xu, Caigang¹ (AUTHOR) xucaigang@wchscu.cn

Source: BMC Cancer. 3/3/2025, Vol. 25 Issue 1, p1-12. 12p.

Subject Terms: *RANDOM effects model, *IMMUNE checkpoint inhibitors, *PROGRAMMED cell death 1 receptors, *ADVERSE health care events, *PROGRAMMED death-ligand 1

Tumour mutational burden using a targeted panel approach for comprehensive tumour profiling focusing on colorectal cancer.

Authors: Scott, Rodney J.^1,2 (AUTHOR) rodney.scott@newcastle.edu.au, Ziolkowski, Andrew¹ (AUTHOR), Mossman, David¹ (AUTHOR), Hipwell, Michael¹ (AUTHOR)

Source: Hereditary Cancer in Clinical Practice. 2/28/2025, Vol. 23 Issue 1, p1-4. 4p.

Subject Terms: *IMMUNE checkpoint inhibitors, *MEDICAL sciences, *COLORECTAL cancer, *INVECTIVE, *TUMORS

m6A RNA methylation: a pivotal regulator of tumor immunity and a promising target for cancer immunotherapy.

Authors: Chen, Xi^1,2 (AUTHOR), Yuan, Yixiao³ (AUTHOR), Zhou, Fan^1,2 (AUTHOR), Li, Lihua² (AUTHOR), Pu, Jun^1,2 (AUTHOR) pujun137@126.com, Jiang, Xiulin³ (AUTHOR) xiulin.jiang@ufl.edu

Source: Journal of Translational Medicine. 2/28/2025, Vol. 23 Issue 1, p1-19. 19p.

Subject Terms: *MEDICAL sciences, *IMMUNE checkpoint inhibitors, *RNA methylation, *RNA splicing, *IMMUNE response

Construction of hot tumor classification models in gastrointestinal cancers.

Authors: Huang, Chien-Jung¹ (AUTHOR), Liu, Guan-Ting² (AUTHOR), Yeh, Yi-Chen^3,4 (AUTHOR), Chung, Shin-Yi⁵ (AUTHOR), Chang, Yu-Chan⁶ (AUTHOR), Chiang, Nai-Jung^4,5,7 (AUTHOR), Lu, Meng-Lun⁵ (AUTHOR), Huang, Wei-Ning¹ (AUTHOR), Chen, Ming-Huang^4,5 (AUTHOR) mhchen9@vghtpe.gov.tw, Wang, Yu-Chao^1,8 (AUTHOR) yuchao@nycu.edu.tw

Source: Journal of Translational Medicine. 2/21/2025, Vol. 23 Issue 1, p1-15. 15p.

Subject Terms: *IMMUNE checkpoint inhibitors, *MEDICAL sciences, *TUMOR classification, *GASTROINTESTINAL cancer, *GENE expression profiling

Enzymatically responsive nanocarriers targeting PD-1 and TGF-β pathways reverse immunotherapeutic resistance and elicit robust therapeutic efficacy.

Authors: Yen, Ying-Tzu¹ (AUTHOR), Zhang, Zhifan¹ (AUTHOR), Chen, Anni² (AUTHOR), Qiu, Yuling¹ (AUTHOR), Liu, Qin¹ (AUTHOR), Wang, Qin¹ (AUTHOR), Li, Chunhua² (AUTHOR), Wang, Chun¹ (AUTHOR), Qian, Xiaoping¹ (AUTHOR), Shao, Jie¹ (AUTHOR), Meng, Fanyan¹ (AUTHOR), Yu, Lixia^1,3 (AUTHOR), Liu, Baorui¹ (AUTHOR) baoruiliu@nju.edu.cn, Li, Rutian^1,3 (AUTHOR) rutianli@nju.edu.cn

Source: Journal of Nanobiotechnology. 2/19/2025, Vol. 23 Issue 1, p1-17. 17p.

Subject Terms: *MEDICAL sciences, *IMMUNE checkpoint inhibitors, *EXTRACELLULAR matrix, *TUMOR-infiltrating immune cells, *TUMOR microenvironment

Integrative analysis of T cell-mediated tumor killing-related genes reveals KIF11 as a novel therapeutic target in esophageal squamous cell carcinoma.

Authors: Cheng, Xinxin¹ (AUTHOR), Zhao, Huihui² (AUTHOR), Li, Zhangwang¹ (AUTHOR), Yan, Liping³ (AUTHOR), Min, Qingjie¹ (AUTHOR), Wu, Qingnan^1,4 (AUTHOR) wuqingnan@bjmu.edu.cn, Zhan, Qimin^1,4,5 (AUTHOR) zhanqimin@bjmu.edu.cn

Source: Journal of Translational Medicine. 2/18/2025, Vol. 23 Issue 1, p1-16. 16p.

Subject Terms: *IMMUNE checkpoint proteins, *IMMUNE checkpoint inhibitors, *MEDICAL sciences, *TREATMENT effectiveness, *SQUAMOUS cell carcinoma

Targeting Heat Shock Transcription Factor 4 Enhances the Efficacy of Cabozantinib and Immune Checkpoint Inhibitors in Renal Cell Carcinoma.

Authors: Saito, Saeki¹ (AUTHOR), Yoshino, Hirofumi^1,2 (AUTHOR) hyoshino@m3.kufm.kagoshima-u.ac.jp, Yokoyama, Seiya^1,2 (AUTHOR), Tominaga, Mitsuhiko^1,2 (AUTHOR), Li, Gang¹ (AUTHOR), Arima, Junya¹ (AUTHOR), Kawahara, Ichiro¹ (AUTHOR), Fukuda, Ikumi¹ (AUTHOR), Mitsuke, Akihiko¹ (AUTHOR), Sakaguchi, Takashi¹ (AUTHOR), Inoguchi, Satoru¹ (AUTHOR), Matsushita, Ryosuke¹ (AUTHOR), Yamada, Yasutoshi¹ (AUTHOR), Tatarano, Shuichi¹ (AUTHOR), Tanimoto, Akihide² (AUTHOR), Enokida, Hideki¹ (AUTHOR)

Source: International Journal of Molecular Sciences. Feb2025, Vol. 26 Issue 4, p1776. 15p.

Subject Terms: *HEAT shock factors, *IMMUNE checkpoint inhibitors, *VASCULAR endothelial growth factors, *RENAL cell carcinoma, *PROTEIN-tyrosine kinase inhibitors

Immunogenic Cell Death Inducers in Cancer Immunotherapy to Turn Cold Tumors into Hot Tumors.

Authors: Lucarini, Valeria^1,2 (AUTHOR), Melaiu, Ombretta^1,2,3 (AUTHOR), Gragera, Paula^1,3 (AUTHOR), Król, Kamila^1,4 (AUTHOR), Scaldaferri, Valentina¹ (AUTHOR), Damiani, Verena^1,2 (AUTHOR), De Ninno, Adele^3,4 (AUTHOR), Nardozi, Daniela^2,4 (AUTHOR), Businaro, Luca⁴ (AUTHOR), Masuelli, Laura² (AUTHOR), Bei, Roberto³ (AUTHOR), Cifaldi, Loredana³ (AUTHOR), Fruci, Doriana¹ (AUTHOR) doriana.fruci@opbg.net

Source: International Journal of Molecular Sciences. Feb2025, Vol. 26 Issue 4, p1613. 12p.

Subject Terms: *IMMUNE checkpoint inhibitors, *KILLER cells, *CHILDHOOD cancer, *CELL death, *TUMOR microenvironment, *T cells

Divide and Conquer—Targeted Therapy for Triple-Negative Breast Cancer.

Authors: Nedeljković, Milica¹ (AUTHOR) mnedel30@tutanota.com, Vuletić, Ana¹ (AUTHOR), Mirjačić Martinović, Katarina¹ (AUTHOR)

Source: International Journal of Molecular Sciences. Feb2025, Vol. 26 Issue 4, p1396. 55p.

Subject Terms: *TRIPLE-negative breast cancer, *IMMUNE checkpoint inhibitors, *PI3K/AKT pathway, *PHOSPHATIDYLINOSITOL 3-kinases, *BREAST cancer

Soluble TIM-3, likely produced by myeloid cells, predicts resistance to immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma.

Authors: Pourmir, Ivan^1,2,3,4 (AUTHOR) ivan.pourmir@aphp.fr, Benhamouda, Nadine^1,5 (AUTHOR), Tran, Thi¹ (AUTHOR), Roux, Hugo⁶ (AUTHOR), Pineau, Joséphine^1,5 (AUTHOR), Gey, Alain^1,5 (AUTHOR), Munoz, Andyara⁵ (AUTHOR), Mabrouk, Nesrine⁵ (AUTHOR), Epaillard, Nicolas⁷ (AUTHOR), Verkarre, Virginie⁸ (AUTHOR), Vano, Yann-Alexandre^9,10 (AUTHOR), Tartour, Eric^1,4,5 (AUTHOR) eric.tartour@inserm.fr, Oudard, Stéphane^1,2,4 (AUTHOR) stephane.oudard@aphp.fr

Source: Journal of Experimental & Clinical Cancer Research (17569966). 2/14/2025, Vol. 44 Issue 1, p1-12. 12p.

Subject Terms: *MEDICAL sciences, *IMMUNE checkpoint inhibitors, *MYELOID cells, *RENAL cell carcinoma, *IMMUNE checkpoint proteins

MAP1LC3C repression reduces CIITA- and HLA class II expression in non-small cell lung cancer.

Authors: Barbeau, Lydie M. O.¹ (AUTHOR), Beelen, Nicky A.^2,3 (AUTHOR), Savelkouls, Kim G.¹ (AUTHOR), Keulers, Tom G. H.¹ (AUTHOR), Wieten, Lotte³ (AUTHOR), Rouschop, Kasper M. A.¹ (AUTHOR) kasper.rouschop@maastrichtuniversity.nl

Source: PLoS ONE. 2/10/2025, Vol. 20 Issue 2, p1-19. 19p.

Subject Terms: *NON-small-cell lung carcinoma, *IMMUNE checkpoint inhibitors, *SQUAMOUS cell carcinoma, *PROGRESSION-free survival, *LUNG cancer

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system.

Authors: Gao, Ruichen¹ (AUTHOR), Liang, Wenjun¹ (AUTHOR), Chen, Jintao¹ (AUTHOR), Yang, Mingxia¹ (AUTHOR), Yu, Xiaowei¹ (AUTHOR), Wang, Xiaohua¹ (AUTHOR) xiaohuawang001@foxmail.com

Source: BMC Cancer. 2/7/2025, Vol. 25 Issue 1, p1-9. 9p.

Subject Terms: *IMMUNE checkpoint inhibitors, *NON-small-cell lung carcinoma, *BAYESIAN analysis, *NIVOLUMAB, *ATEZOLIZUMAB

Company/Entity: UNITED States. Food & Drug Administration

Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients.

Authors: Azzariti, Amalia¹ (AUTHOR) a.azzariti@oncologico.bari.it, De Summa, Simona² (AUTHOR), Marvulli, Tommaso M.³ (AUTHOR), De Risi, Ivana⁴ (AUTHOR), De Palma, Giuseppe⁵ (AUTHOR), Di Fonte, Roberta¹ (AUTHOR), Fasano, Rossella¹ (AUTHOR), Serratì, Simona¹ (AUTHOR), Strippoli, Sabino⁴ (AUTHOR), Porcelli, Letizia¹ (AUTHOR), Guida, Michele⁴ (AUTHOR)

Source: Journal of Experimental & Clinical Cancer Research (17569966). 2/6/2025, Vol. 44 Issue 1, p1-14. 14p.

Subject Terms: *DISEASE risk factors, *IMMUNE checkpoint inhibitors, *PROGRAMMED death-ligand 1, *OVERALL survival, *PROGRESSION-free survival

Production of novel theranostic nano-vector based on superparamagnetic iron oxide nanoparticles/miR-497 targeting colorectal cancer.

Authors: Elfiky, Asmaa M.¹ (AUTHOR) am.elfiky@nrc.sci.eg, Eid, May M.² (AUTHOR), El-Manawaty, May³ (AUTHOR), Elshahid, Zeinab A.⁴ (AUTHOR), Youssef, Elham Mohamed⁵ (AUTHOR), Mahmoud, Khaled³ (AUTHOR)

Source: Scientific Reports. 2/4/2025, Vol. 15 Issue 1, p1-13. 13p.

Subject Terms: *IMMUNE checkpoint inhibitors, *OPTICAL spectroscopy, *FOURIER transform infrared spectroscopy, *FERRIC oxide, *CELL lines, *MAGNETIC particle imaging

Single-cell landscape of dynamic changes in CD8⁺ T cells, CD4⁺ T cells and exhausted T cells in hepatocellular carcinoma.

Authors: Liu, Rongqiang¹ (AUTHOR), Ye, Jing¹ (AUTHOR), Wang, Jianguo¹ (AUTHOR), Ma, Wangbin¹ (AUTHOR), Qiu, Zhendong¹ (AUTHOR), Yu, Jia¹ (AUTHOR) yogaqq116@whu.edu.cn, Wang, Weixing¹ (AUTHOR) wangwx@whu.edu.cn

Source: Scientific Reports. 2/3/2025, Vol. 15 Issue 1, p1-12. 12p.

Subject Terms: *T-cell exhaustion, *IMMUNE checkpoint inhibitors, *T cells, *MEDICAL sciences, *HEPATOCELLULAR carcinoma